Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Free Cash Flow (2016 - 2025)

China Pharma Holdings' Free Cash Flow history spans 16 years, with the latest figure at $73275.0 for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 73.76% year-over-year to $73275.0; the TTM value through Dec 2025 reached $10676.0, up 102.56%, while the annual FY2025 figure was $10676.0, 102.4% up from the prior year.
  • Free Cash Flow reached $73275.0 in Q4 2025 per CPHI's latest filing, up from -$237598.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $939831.0 in Q3 2023 to a low of -$1.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$130064.8, with a median of -$95525.0 recorded in 2024.
  • Peak YoY movement for Free Cash Flow: soared 2911.59% in 2023, then tumbled 529.7% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$205168.0 in 2021, then soared by 398.22% to $611862.0 in 2022, then plummeted by 104.39% to -$26850.0 in 2023, then soared by 1139.96% to $279228.0 in 2024, then crashed by 73.76% to $73275.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Free Cash Flow are $73275.0 (Q4 2025), -$237598.0 (Q3 2025), and $293323.0 (Q2 2025).